Recombinant DNA Technology Market Report 2025

The recombinant DNA technology market size has grown strongly in recent years. It will grow from $858.94 billion in 2024 to $920.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to healthcare demands, biopharmaceutical industry growth, rising investments in R&D, emergence of personalized medicine.

The recombinant DNA technology market size is expected to see strong growth in the next few years. It will grow to $1.31 trillion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to rising chronic diseases, emerging biotech startups, increasing funding in biotech, globalization of biotech markets, consumer acceptance and education. Major trends in the forecast period include scientific advancements, gene editing advancements, cell and gene therapies, development of RNA therapeutics, therapeutic applications in rare diseases, AI and data integration.

The rising prevalence of chronic diseases is anticipated to drive the growth of the recombinant DNA technology market. Chronic diseases, defined as conditions lasting a year or more that require ongoing medical attention or limit daily activities, significantly impact healthcare needs. Recombinant DNA technology has transformed healthcare by enabling the development of biopharmaceutical proteins used in medications and facilitating gene therapy to replace defective genes with healthy ones, aiming for disease cures. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, there would be over 35 million new cancer cases, reflecting a 77% increase from the estimated 20 million cases in 2022. Thus, the rise in chronic diseases is propelling the growth of the recombinant DNA technology market.

The growing advancement of genetically modified crops is projected to drive the expansion of the recombinant DNA technology market in the future. Genetically modified crops are plants that have been intentionally altered at the genetic level using biotechnological methods. Recombinant DNA (rDNA) technology is utilized in the development of genetically modified (GM) crops by isolating genes that provide desired traits, creating recombinant DNA, inserting it into host crop cells, selecting and screening for successful integrations, regenerating transgenic plants, verifying trait expression, conducting field trials, securing regulatory approvals, and ultimately commercializing crops with enhanced characteristics. For example, in December 2023, the United States Department of Agriculture, a US-based government agency, reported that Canada planted 11.7 million hectares of genetically engineered (GE) crops, mainly including canola, soybeans, and corn. This marks a four percent increase from the previous year, largely due to the expansion of canola planting areas. Consequently, the growing development of genetically modified crops is fueling the growth of the recombinant DNA technology market.

Technological advancement is a significant trend within the recombinant DNA technology market. Leading companies in this sector are concentrating on innovative technologies to maintain their competitive edge. For example, in August 2022, Bluebird Bio, Inc., a US-based biotechnology firm, introduced ZYNTEGLO, which received approval from the U.S. Food and Drug Administration (FDA). This one-time gene therapy addresses beta-thalassemia by targeting its genetic cause, providing patients with the opportunity to achieve independence from regular red blood cell transfusions. ZYNTEGLO utilizes an ex-vivo lentiviral vector to modify patient cells and is the first FDA-approved gene therapy for this condition in the United States. This groundbreaking therapy significantly alleviates the lifelong burden associated with managing beta-thalassemia.

Moreover, major players within the recombinant DNA technology sector are actively engaged in developing new vaccines to sustain their market presence. For instance, Variation Biotechnologies Inc. launched PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] in March 2022 in the United States. This vaccine, approved by the FDA in November 2021, incorporates essential hepatitis B surface antigens, ensuring a robust immune response when administered in a 3-dose series. The development and launch of such vaccines represent a significant stride within the recombinant DNA technology market.

In January 2022, Thermo Fisher Scientific, a prominent supplier based in the US specializing in scientific instrumentation, reagents, consumables, and software services, finalized the acquisition of PeproTech for a sum of $1.85 billion. This strategic acquisition aimed to complement Thermo Fisher's existing line of cell culture media products by integrating PeproTech's extensive portfolio of recombinant proteins. By combining these offerings, Thermo Fisher sought to deliver enhanced advantages to its customers through an integrated solution. PeproTech, Inc., the acquired company, is recognized for its expertise as a US-based developer and manufacturer of bioscience reagents, particularly renowned for its recombinant proteins.

Major companies operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.

North America was the largest region in the recombinant DNA technology market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the recombinant dna technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Recombinant DNA technology denotes the fusion of DNA molecules from diverse organisms, integrating them into a host organism to create new genetic combinations beneficial across scientific, medical, agricultural, and industrial domains. This technology plays a pivotal role in addressing health concerns by facilitating the development of novel medications and vaccines.

Within the realm of recombinant DNA technology, key product categories encompass recombinant protein drugs, vaccines, genetically modified crops, expression systems, cell and gene therapy, and gene editing. Notably, recombinant protein drugs serve crucial roles in biochemical analysis and medical diagnostics within human healthcare, including the production of antibodies, medicines, and vaccines. Renowned for their potency and rapid development compared to small molecules, these drugs are considered safer due to their reduced off-target adverse effects. This category comprises components like expression systems and cloning vectors. The extensive applications of recombinant DNA technology span various sectors such as food and agriculture, health and disease management, environmental interventions, and other diverse areas. This technology finds practical usage in biotechnology and pharmaceutical companies, academic and government research institutions, and various other end-use industries. Its impact is notably significant across a wide spectrum of fields and industries.

The recombinant DNA technology market research report is one of a series of new reports that provides recombinant DNA technology market statistics, including recombinant DNA technology industry global market size, regional shares, competitors with an recombinant DNA technology market share, detailed recombinant DNA technology market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant DNA technology industry. This recombinant DNA technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The recombinant DNA technology market includes revenues earned by entities by expression systems including mammalian, bacteria, yeast, and baculovirus / insect. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.